Browsing Tag
Novartis
83 posts
Inside the Crucial Catch partnership: how the American Cancer Society and NFL are tackling cancer disparities with new grants
Discover how the American Cancer Society and NFL’s Crucial Catch program is boosting cancer screening access and saving lives nationwide.
The Max Foundation and Novartis deepen global cancer care partnerships with a pledge to reach 100,000 patients annually by 2030
The Max Foundation and Novartis pledge to expand global cancer care, targeting 100,000 patients annually by 2030 with systemic, equity-driven partnerships.
Kashiv BioSciences bets on Latin America with Cristália deal for Xolair biosimilar
Kashiv BioSciences partners with Brazil’s Cristália to commercialize omalizumab biosimilar ADL-018 in Latin America, targeting a $140M market opportunity.
Can asciminib reshape first-line CML treatment? Inside Scemblix’s rise as a new standard of care in Canada
More than a month after Health Canada’s approval, Scemblix is forcing a rethink of chronic myeloid leukemia therapy—and raising the bar for tolerability and precision.
Daiichi Sankyo launches development of oral triple combination tablets for LDL cholesterol management in Europe
Daiichi Sankyo (TYO: 4568) begins developing oral triple therapy with bempedoic acid, ezetimibe, and statins to transform LDL cholesterol management in Europe.
Syngenta expands global footprint in agricultural biologicals with new acquisitions and facilities
Syngenta advances global leadership in agricultural biologicals with new acquisitions, R&D centers, and a USD 20B market outlook by 2030. Explore strategy.
Top 5 PCSK9 inhibitor stocks to watch in 2025: From injectables to gene editing
Explore the top five PCSK9 inhibitor stocks—Amgen, Regeneron–Sanofi, Merck, Novartis, Verve—and what makes each a standout in cholesterol treatment in 2025.
The race for non-opioid pain relief: who’s leading the post-opioid era?
Explore the top companies and mechanisms leading the post-opioid pain relief revolution in 2025. Who's winning the race for safe, effective chronic pain drugs?
Biotech layoffs 2025: Prothena joins the wave—What’s driving the restructuring trend?
Explore why Prothena’s layoffs reflect a growing 2025 biotech downsizing trend. What’s causing the wave, and who might be next?
Novartis to acquire Regulus Therapeutics in $1.7bn deal to advance farabursen for ADPKD treatment
Novartis to acquire Regulus Therapeutics for $1.7 billion, gaining next-gen kidney drug farabursen for ADPKD. Read the market reaction and deal insights.